Literature DB >> 9113958

Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. The Neonatal Brain Hemorrhage Study Analysis Group.

N Paneth1, J Jetton, J Pinto-Martin, M Susser.   

Abstract

OBJECTIVES: We tested the hypothesis that administration of magnesium sulfate in labor protects against the development of neonatal brain lesions and cerebral palsy (CP) in low birth weight infants.
METHODS: Magnesium exposure was ascertained in a population-based cohort of 1105 infants weighing 2000 g or less through review of medical records of maternal magnesium sulfate administration and, where available, elevated maternal serum magnesium levels. Neonatal germinal matrix/intraventricular hemorrhage and parenchymal brain lesions were ascertained by a prospective, timed ultrasound scanning protocol in the first week of life. CP was ascertained at 2 years of age by clinical examination in 80% of survivors and by interview and medical record review in another 6% and was classified as disabling or nondisabling.
RESULTS: No significant reduction in risk of nondisabling CP (adjusted odds ratio [OR], 1.00; 95% confidence interval [CI], 0.53 to 1.88) or disabling CP [DCP] (adjusted OR, 0.63; 95% CI, 0.32 to 1.24) CP with magnesium exposure was found in a logistic regression model that controlled for gestational age, fetal growth, gender, multiple birth status, mode of delivery, amnionitis, and hypertensive disorders. In a small subset of infants, those with onset of parenchymal lesions at 7 days of age or later (n = 29), magnesium exposure was associated with a significantly reduced risk of DCP (OR, 0.10; 95% CI, 0.02 to 0.65). Magnesium sulfate exposure was not associated with germinal matrix/intraventricular hemorrhage (adjusted OR, 0.89; 95% CI, 0.64 to 1.25) or with parenchymal brain lesions (adjusted OR, 0.83; 95% CI, 0.53 to 1.30).
CONCLUSIONS: The hypothesis that magnesium sulfate use reduces the risk of neonatal brain lesions or CP in low birth weight infants was not statistically supported in this study, although a modest reduction in risk of DCP cannot be excluded. The data further suggest that magnesium exposure may be associated with reduction in risk of CP in low birth weight infants who have late-onset brain lesions, but this unpredicted observation requires confirmation in another data set.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9113958     DOI: 10.1542/peds.99.5.e1

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

Review 1.  Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles.

Authors:  J F Lu; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Antenatal magnesium sulfate and spontaneous intestinal perforation in infants less than 25 weeks gestation.

Authors:  B N Rattray; D M Kraus; L R Drinker; R N Goldberg; D T Tanaka; C M Cotten
Journal:  J Perinatol       Date:  2014-06-05       Impact factor: 2.521

3.  Magnesium sulfate tocolysis and intraventricular hemorrhage in very preterm infants.

Authors:  Anna Petrova; Rajeev Mehta
Journal:  Indian J Pediatr       Date:  2011-05-28       Impact factor: 1.967

4.  Use and attitudes of obstetricians toward 3 high-risk interventions in MFMU Network hospitals.

Authors:  Sabine Zoghbi Bousleiman; Madeline Murguia Rice; Joan Moss; Allison Todd; Monica Rincon; Gail Mallett; Cynthia Milluzzi; Donna Allard; Karen Dorman; Felecia Ortiz; Francee Johnson; Peggy Reed; Susan Tolivaisa
Journal:  Am J Obstet Gynecol       Date:  2015-05-06       Impact factor: 8.661

5.  Antenatal Magnesium and Cerebral Palsy in Preterm Infants.

Authors:  Deborah G Hirtz; Steven J Weiner; Dorothy Bulas; Michael DiPietro; Joanna Seibert; Dwight J Rouse; Brian M Mercer; Michael W Varner; Uma M Reddy; Jay D Iams; Ronald J Wapner; Yoram Sorokin; John M Thorp; Susan M Ramin; Fergal D Malone; Marshall W Carpenter; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Donald Dudley; Steve N Caritis
Journal:  J Pediatr       Date:  2015-08-05       Impact factor: 4.406

6.  High dose magnesium sulfate exposure induces apoptotic cell death in the developing neonatal mouse brain.

Authors:  William H Dribben; Catherine E Creeley; Hai Hui Wang; Derek J Smith; Nuri B Farber; John W Olney
Journal:  Neonatology       Date:  2009-02-10       Impact factor: 4.035

Review 7.  Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.

Authors:  Agustín Conde-Agudelo; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2009-06       Impact factor: 8.661

8.  The use of antenatal magnesium sulfate for neuroprotection for infants born prematurely.

Authors:  Kent Heyborne; Watson A Bowes
Journal:  F1000 Med Rep       Date:  2010-11-11

Review 9.  Fetal Neuroprotective Strategies: Therapeutic Agents and Their Underlying Synaptic Pathways.

Authors:  Nada A Elsayed; Theresa M Boyer; Irina Burd
Journal:  Front Synaptic Neurosci       Date:  2021-06-23

10.  Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol.

Authors:  Caroline A Crowther; Philippa F Middleton; Dominic Wilkinson; Pat Ashwood; Ross Haslam
Journal:  BMC Pregnancy Childbirth       Date:  2013-04-09       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.